Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats

Psychopharmacology

Volumn 195, Issue 3, 2007, Pages 387-395

  Lee, Li Yen ^a   Ong, Wei Yi ^a   Farooqui, Akhlaq A ^c   Burgunder, Jean Marc ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Arachidonic acid; Basal ganglia; Calcium independent phospholipase A2; Parkinson's disease; Tremor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BENZATROPINE; BROMOENOL LACTONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; METHYL ARACHIDONYL FLUOROPHOSPHONATE; PHOSPHATE BUFFERED SALINE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MASTICATION; MOTOR CORTEX; MOTOR SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; THALAMUS;

ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; BENZTROPINE; CALCIUM; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE UPTAKE INHIBITORS; DRUG ADMINISTRATION ROUTES; ENZYME INHIBITORS; MALE; NAPHTHALENES; OLIGONUCLEOTIDES, ANTISENSE; ORGAN SPECIFICITY; PHOSPHODIESTERASE INHIBITORS; PHOSPHOLIPASES A2, CALCIUM-INDEPENDENT; PHOSPHONIC ACIDS; PYRONES; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR; THALAMUS;

EID: 36349021926     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0912-y     Document Type: Article

References (47)

1. 2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem 270:445-450
2. Andreassen OA, Jorgensen HA (2000) Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 61:525-541
3. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA (2003) Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122:717-725
4. 2 in nuclei of LA-N-1 neuroblastoma cells. Neurochem Res 26:83-88
5. 2. J Biol Chem 272:16069-16072
6. 2 blocks phospholipid fatty acid remodeling in murine P388D1 macrophages. J Biol Chem 272:29317-29321
7. 2 regulation of arachidonic acid mobilization. FEBS Lett 531:2-6
8. 2) enzymes in membrane trafficking: mediators of membrane shape and function. Traffic 4:214-221
9. Burnett GB, Prange AJ Jr, Wilson IC, Jolliff LA, Creese IC, Synder SH (1980) Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology 6:109-120
10. Cousins MS, Carriero DL, Salamone JD (1997) Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol 322:137-145
11. Egan MF, Hurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM (1996) Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl) 127:337-345
12. Ellison G, See R, Levin E, Kinney J (1987) Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology (Berl) 92:122-126
13. Ellison G, Johansson P, Levin E, See R, Gunne L (1988) Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats. Psychopharmacology 96:253-257
14. Fahn WE, Lake CR, Gerber CJ (1974) Cholinergic suppression of tardive dyskinesia. Psychopharmacology 42:135-137
15. 2 in neurological disorders. Springer, New York
16. 2 signaling in the nucleus. Brain Res Brain Res Rev 45:179-195
17. 2 inhibitor in rat hippocampal slices. Br J Pharmacol 132:1417-1422
18. 2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 22:421-426
19. 2 activity in schizophrenia: a replication study. Biol Psychiatry 28:495-501
20. Iversen SD, Howells RB, Hughes RP (1980) Behavioral consequences of long-term treatment with neuroleptic drugs. Adv Biochem Psychopharmacol 24:305-313
21. Jicha GA, Salamone JD (1991) Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms. J Neurosci 11:3822-3829
22. Katzenschlager R, Sampaio C, Costa J, Lees A (2003) Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2:CD003735
23. Lees A (2005) Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22:731-740
24. 2 in alpha-amino-3-hydroxy-5-methylisoxazole-propionate receptor regulation during long-term potentiation. Eur J Neurosci 23:505-513
25. 2 inhibitors. Neurosci Lett 389:51-56
26. 2 and 5-lipoxygenase activities. Hippocampus 15:370-380
27. 2 activity in primary cultures of rat cortical neurons. J Neural Transm 112:1297-1308
28. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, Johnson CA, Levinson B, Woods CG, Wilmot B, Kramer P, Gitschier J, Maher ER, Hayflick SJ (2006) PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 38:752-754
29. Moriyama T, Urade R, Kito M (1999) Purification and characterization of diacylglycerol lipase from human platelets. J Biochem 125:1077-1085
30. 2 in normal rat brain. J Hirnforsch 39:391-400
31. 2) in monkey brain. J Neurocytol 34:447-458
32. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, San Diego
33. 2. Arch Gen Psychiatry 54:487-494
34. 2 activity in bipolar affective disorder. Bipolar Disord 8:265-270
35. Salamone JD, Lalies MD, Channell SL, Iversen SD (1986) Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology (Berl) 88:467-471
36. Salamone JD, Johnson CJ, McCullough LD, Steinpreis RE (1990) Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology (Berl) 102:529-534
37. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:591-611
38. 2 subtypes in rat cerebellum. J Neurocytol 33:297-307
39. Steinpreis RE, Salamone JD (1993) Effects of acute haloperidol and reserpine administration on vacuous jaw movements in three different age groups of rats. Pharmacol Biochem Behav 46:405-409
40. Steinpreis RE, Baskin P, Salamone JD (1993) Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology (Berl) 111:99-105
41. 2 inhibitors selectively increases AMPA receptor-mediated synaptic transmission. Hippocampus 14:319-325
42. 2+. Br J Pharmacol 139:1014-1022
43. 2. Neuroscience 140:547-553
44. Victor M, Ropper AH (2001) Adam and Victor's Principles of Neurology, 7th edn. McGraw-Hill, New York, p 103
45. 2. FEBS Lett 377:358-362
46. 2 from rat brain. J Neurochem 73:128-1278
47. 2 inhibitors modulates allodynia after facial carrageenan injection in mice. Pain 112:148-155